Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?

Translational Oncology

Emmanuel Seront¹  Hélène Houssiau² 

[1] Corresponding author.;Department of Medical Oncology, Centre Hospitalier de Jolimont, Rue Ferrer 159, 7100 Haine Saint Paul, Belgium;

关键词: Urothelial carcinoma;    Immune checkpoint inhibitors;    Maintenance strategy;    PD-L1;    Platinum-based strategy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with metastatic urothelial cancer (mUC). If these agents were first used in monotherapy after failure of platinum-based chemotherapy, new strategies have been evaluated in the last years, including association of ICIs, ICI plus chemotherapy association or maintenance therapy. This maintenance concept allows a better management of mUC, which is particularly interesting in cisplatin-ineligible patients.This paper aims to review the current knowledge of ICIs in urothelial carcinoma as well as the new indications of these agents in mUC.

【 授权许可】

Unknown